Список литературы к Главе 4

144. Gomes de Castro M.A., Wildhagen H., Sograte-Idrissi S., Hitzing C., Binder M., Trepel M. et al. Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane // Nat. Commun. 2019. Vol. 10, N 1. P. 820.

145. Minici C., Gounari M., Ubelhart R., Scarfo L., Duhren-von Minden M., Schneider D. et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia // Nat. Commun. 2017. Vol. 8. Article ID 15746.

146. Lanham S., Hamblin T., Oscier D., Ibbotson R., Stevenson F., Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia // Blood. 2003. Vol. 101, N 3. P. 1087–1093.

147. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A. et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia // Blood. 2002. Vol. 100, N 13. P. 4609–4614.

148. Mockridge C.I., Potter K.N., Wheatley I., Neville L.A., Packham G., Stevenson F.K. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status // Blood. 2007. Vol. 109, N 10. P. 4424–4431.

149. Muzio M., Apollonio B., Scielzo C., Frenquelli M., Vandoni I., Boussiotis V. et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy // Blood. 2008. Vol. 112, N 1. P. 188–195.

150. Apollonio B., Scielzo C., Bertilaccio M.T., Ten Hacken E., Scarfo L., Ranghetti P. et al. Targeting B-cell anergy in chronic lymphocytic leukemia // Blood. 2013. Vol. 121, N 19. P. 3879–3888, S3871–S3878.

151. Stamatopoulos B., Meuleman N., De Bruyn C., Pieters K., Mineur P., Le Roy C. et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments // Haematologica. 2012. Vol. 97, N 4. P. 608–615.

152. Andritsos L.A., Byrd J.C., Cheverton P., Wu J., Sivina M., Kipps T.J. et al. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2019. Vol. 60, N 14. P. 3461–3469.

153. Hoellenriegel J., Zboralski D., Maasch C., Rosin N.Y., Wierda W.G., Keating M.J. et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization // Blood. 2014. Vol. 123, N 7. P. 1032–1039.

154. Steurer M., Montillo M., Scarfo L., Mauro F.R., Andel J., Wildner S. et al. Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia // Haematologica. 2019. Vol. 104, N 10. P. 2053–2060.

155. Ahn I.E., Farooqui M.Z.H., Tian X., Valdez J., Sun C., Soto S. et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study // Blood. 2018. Vol. 131, N 21. P. 2357–2366.

156. O’Brien S., Furman R.R., Coutre S., Flinn I.W., Burger J.A., Blum K. et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience // Blood. 2018. Vol. 131, N 17. P. 1910–1919.

157. Coutre S.E., Furman R.R., Flinn I.W., Burger J.A., Blum K., Sharman J. et al. Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma // Clin. Cancer Res. 2017. Vol. 23, N 5. P. 1149–1155.

158. Burger J.A., Li K.W., Keating M.J., Sivina M., Amer A.M., Garg N. et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib // JCI Insight. 2017. Vol. 2, N 2. Article ID e89904.

159. Cheng S., Ma J., Guo A., Lu P., Leonard J.P., Coleman M. et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity // Leukemia. 2014. Vol. 28, N 3. P. 649–657.

160. Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 // Blood. 2011. Vol. 117, N 23. P. 6287–6296.

161. de Rooij M.F., Kuil A., Geest C.R., Eldering E., Chang B.Y., Buggy J.J. et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 11. P. 2590–2594.

162. Hoellenriegel J., Coffey G.P., Sinha U., Pandey A., Sivina M., Ferrajoli A. et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration // Leukemia. 2012. Vol. 26, N 7. P. 1576–1583.

163. Yeh Y.Y., Ozer H.G., Lehman A.M., Maddocks K., Yu L., Johnson A.J. et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling // Blood. 2015. Vol. 125, N 21. P. 3297–3305.

164. Niemann C.U., Herman S.E., Maric I., Gomez-Rodriguez J., Biancotto A., Chang B.Y. et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib – findings from an investigator-initiated phase II study // Clin. Cancer Res. 2016. Vol. 22, N 7. P. 1572–1582.

165. Ping L., Ding N., Shi Y., Feng L., Li J., Liu Y. et al. The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages // Oncotarget. 2017. Vol. 8, N 24. P. 39 218–39 229.

166. Yin Q., Sivina M., Robins H., Yusko E., Vignali M., O’Brien S. et al. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia // J. Immunol. 2017. Vol. 198, N 4. P. 1740–1747.

167. Long M., Beckwith K., Do P., Mundy B.L., Gordon A., Lehman A.M. et al. Ibrutinib treatment improves T cell number and function in CLL patients // J. Clin. Invest. 2017. Vol. 127, N 8. P. 3052–3064.

168. Kondo K., Shaim H., Thompson P.A., Burger J.A., Keating M., Estrov Z. et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway // Leukemia. 2018. Vol. 32, N 4. P. 960–970.

169. Chen C.I., Paul H., Wang T., Le L.W., Dave N., Kukreti V. et al. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia // Br. J. Haematol. 2014. Vol. 165, N 5. P. 731–733.

170. Acebes-Huerta A., Huergo-Zapico L., Gonzalez-Rodriguez A.P., Fernandez-Guizan A., Payer A.R., Lopez-Soto A. et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells // Biomed. Res. Int. 2014. Vol. 2014. Article ID 265840.

171. Fecteau J.F., Corral L.G., Ghia E.M., Gaidarova S., Futalan D., Bharati I.S. et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53 // Blood. 2014. Vol. 124, N 10. P. 1637–1644.

172. Schulz A., Durr C., Zenz T., Dohner H., Stilgenbauer S., Lichter P. et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment // Blood. 2013. Vol. 121, N 13. P. 2503–2511.

173. Fiorcari S., Martinelli S., Bulgarelli J., Audrito V., Zucchini P., Colaci E. et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia // Haematologica. 2015. Vol. 100, N 2. P. 253–262.

174. Itchaki G., Brown J.R. Lenalidomide in the treatment of chronic lymphocytic leukemia // Expert Opin. Investig. Drugs. 2017. Vol. 26, N 5. P. 633–650.

175. Lee B.N., Gao H., Cohen E.N., Badoux X., Wierda W.G., Estrov Z. et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia // Cancer. 2011. Vol. 117, N 17. P. 3999–4008.

176. Galustian C., Meyer B., Labarthe M.C., Dredge K., Klaschka D., Henry J. et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells // Cancer Immunol. Immunother. 2009. Vol. 58, N 7. P. 1033–1045.